Thus, patients with EGFRm+ NSCLC with true high-level MET amplification at baseline may harbor clones of MET-driven tumor cells that may very rapidly take over when EGFR signaling is inhibited and may cause intrinsic resistance to EGFR-TKIs, resulting in very rapid cancer progression [6,73]. The gene discussed is MET; the disease is neoplasm.